李氏大药厂中期报告2022

中期INTERIM报告REPORT 2022 仅供识别 INTERIMFINANCIALSTATEMENTS Thedirectors(the“Directors”)ofLee’sPharmaceuticalHoldingsLimited(the“Company”)presentherewiththeunauditedconsolidatedinterimfinancialresults(the“InterimResults”)oftheCompanyanditssubsidiaries(collectively,the“Group”)forthesixmonthsended30June2022,togetherwiththecomparativefiguresforthecorrespondingperiodin2021.TheInterimResultsareunaudited,buthavebeenreviewedbytheCompany’sauditor,HLMCPALimited(the“Auditor”)inaccordancewithHongKongStandardonReviewEngagements2410“ReviewofInterimFinancialInformationPerformedbytheIndependentAuditoroftheEntity”issuedbytheHongKongInstituteofCertifiedPublicAccountants(“HKICPA”).TheauditcommitteeoftheCompanyhasalsoreviewedwiththemanagementandtheAuditortheInterimResultsbeforerecommendingittotheboardofDirectors(the“Board”)forapproval. 中期财务报表 李氏大药厂控股有限公司（“本公司”）董事 （“董事”）谨此呈报本公司及其附属公司 （统称“本集团”）截至二零二二年六月三十 日止六个月之未经审核综合中期财务业绩 （“中期业绩”）连同二零二一年同期之比较数字。中期业绩未经审核，惟获本公司核数师恒健会计师行有限公司（“核数师”）按照香港会计师公会颁布之《香港审阅工作准则》第2410号“实体的独立核数师对中期财务资料的审阅”进行审阅。本公司审核委员会于向董事会推荐中期业绩以供批准前，亦已与管理层及核数师审阅中期业绩。 BUSINESSREVIEW RevenueandProfit Duringthesecond-quarter2022,theimplementationofstringentlockdownmeasuresinmajorcitiesinChinatocontaintheoutbreakofCOVIDhasposedsignificantbusinessdisruptionandsupplychainchallenges.Seeingdecentsalesgrowthduringtheperiodunderreviewistrulyablissunderthepresentpersistentlysaggingeconomyintheregion. First-half2022revenueoftheGrouptotalledHK$649,166,000(First-half2021:HK$584,052,000),anincreaseof11.1%comparedtothesameperiodlastyear.Second-quarter2022revenueoftheGrouptotalledHK$324,416,000(Second-quarter2021:HK$300,910,000),anincreaseof7.8%comparedtotheprior-yearquarter.Salesgrowthinthefirst-half2022wasprimarilydrivenbythecontributionsfromthenewlylaunchedBredinin™,aswellasTreprostinilInjectionandYallaferon®whichgrewby48.9%and4.7%,respectively,andoffsetlowersalesofout-patientdrugssuchasFerplex®andsurgicaldrugssuchasLivaracine®andSlounase®. Salesoflicensed-inproductsinthefirst-half2022accountedfor61.2%(First-half2021:57.3%)oftheGroup’srevenuewhilesalesofproprietaryandgenericproductsinthefirst-half2022contributed38.8%(First-half2021:42.7%)oftheGroup’srevenue. 业务回顾 收益及溢利 于二零二二年第二季度，中国多个主要城市实施严格封城措施，以遏止COVID疫情，对业务造成严重干扰，并且为供应链带来挑战。在当前区内经济持续放缓的情况下，回顾期间的销售额录得理想增长，实在难能可贵。 二零二二年上半年，本集团的收益合共为 649,166,000港元（二零二一年上半年： 584,052,000港元），较去年同期增加 11.1%。本集团二零二二年第二季度的收益合共为324,416,000港元（二零二一年第二季度：300,910,000港元），较去年同一季度增加7.8%。二零二二年上半年销售额录得增长，主要受到新推出的 《布累迪宁》TM以及曲前列尼尔注射液及《尤靖安》®贡献的销售额（分别上升48.9%及4.7%）带动，抵销了《菲普利》®等门诊药物以及《立迈青》®及《速乐涓》®等外科药物的销售额跌幅。 引进产品于二零二二年上半年的销售额占本集团收益61.2%（二零二一年上半年：57.3%），而专利产品及仿制产品于二零二二年上半年的销售额则占本集团收益38.8%（二零二一年上半年：42.7%）。 First-half2022grossprofitoftheGroupwasHK$419,478,000(First-half2021:HK$386,546,000),anincreaseof8.5%comparedtothesameperiodlastyear.Second-quarter2022grossprofitoftheGroupwasHK$203,652,000(Second-quarter2021:HK$194,135,000),anincreaseof4.9%comparedtotheprior-yearquarter.Second-quarter2022grossprofitmarginoftheGroupwas62.8%,decreasedby1.7percentagepointsascomparedto64.5%achievedduringtheprior-yearquarter.TheGroup’soverallgrossprofitmarginwas64.6%,decreasedby1.6percentagepointsasto66.2%achievedinthefirst-half2021duetoincreaseinproportionofrevenuegeneratedfromthesalesoflicensed-inproducts. Researchanddevelopment(“R&D”)expensesrepresentednewdrugsdevelopmentinmajortherapeuticareassuchascardiovascular,womanhealth,paediatrics,rarediseases,dermatologyandobstetrics,aswellasinoncologyunderaseparateR&DarmwithintheGroup.AnaggregateofHK$206,517,000hasbeenspentinthefirst-half2022(First-half2021:HK$240,043,000),decreasedby14.0%comparedtothesameperiodlastyearandrepresented31.8%tothecorrespondingrevenuefortheperiod(First-half2021:41.1%).AmongwhichHK$116,590,000 (First-half2021:HK$112,899,000)hasbeenrecognisedasexpensesandHK$89,927,000(First-half2021:HK$127,144,000)hasbeencapitalisedasintangibleassets.TheGroupcontinuestooptimisetheresourcesallocationamongprioritisedR&Dprojectsandthecost-savingeffectthereofhas beguntoshow. 于二零二二年上半年，本集团录得毛利 419,478,000港元（二零二一年上半年： 386,546,000港元），较去年同期增长 8.5%。本集团二零二二年第二季度的毛利为203,652,000港元（二零二一年第二季度：194,135,000港元），较去年同一季度增长4.9%。本集团二零二二年第二季度的毛利率为62.8%，较去年同一季度的64.5%下降1.7个百分点。本集团的整体毛利率为64.6%，较二零二一年上半年的66.2%下降1.6个百分点，是由于引进产品销售额占收益的比例上升。 研究及开发（“研发”）费用来自心血管、女性健康、儿科、罕见病、皮肤科及产科等各个主要治疗领域的新药开发，以及本集团内的独立肿瘤科研发分支。本集团于二零二二年上半年耗资合计206,517,000港元（二零二一年上半年：240,043,000港元），较去年同期减少14.0%，且相当于相应期间收益31.8%（二零二一年上半年：41.1%），当中116,590,000港元 （二零二一年上半年：112,899,000港元）已确认为费用，而89,927,000港元（二零二一年上半年：127,144,000港元）已资本化作为无形资产。本集团继续优化各优先研发项目的资源分配，减省成本的效果开始浮现。 TheGroup’ssellinganddistributionexpenseswasHK$176,215,000inthefirst-half2022,representinganincreaseofHK$12,097,000or7.4%comparedtoHK$164,118,000inthesameperiodlastyear.Overall,thesellingexpensestorevenueratioduringthefirst-half2022was27.1%,slightlydecreasedby1.0percentagepointasto28.1%sameperiodlastyear.InMarch2022,theGrouphaslauncheditsownflagshiponlinestoresone-commerceplatformofAlibaba.comandJD.comtostrengthenitsbrandawarenessandexpanditssaleschannels.TheGroupcontinuestodep